Partners
The Consortium brings together scientists and researchers globally from the fields of clinical trial design and implementation, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.
Our research group has joined the consortium at its foundation in 2008 and remained in a close partnership ever since.
Together, we deliver high quality clinical and laboratory research, deliver trainings across the partner sites and support capacity development in Africa.
The University of St Andrews is one of the 16 international institutes of the PanACEA Consortium.
LifeArc charity-based non-profit organisation supporting the translation of promising science into patient treatments and diagnostics.
Our research group has partnered LifeArc in 2018 in a joined force to translate TB-MBLA into a commercially available diagnostic and treatment monitoring tool.
Since then, LifeArc scientists at the Centre for Diagnostic Development have formed a TB-MBLA development team and have evaluated, standardised, and improved the assay.
Radboudumc is a teaching hospital affiliated with the Radboud University in Nijmegen. It is also the headquarter of the PanACEA II Consortium. Their scientific research team specialises in pharmacodynamic and pharmacokinetic modelling of TB clinical trial data and microbiology.
Radboudumc is also co-leading UNITE4TB a new consortium that the University of St Andrews research team has partnered with.
UNITE4TB is a new consortium established in 2021 as a public-private partnership with representation from academic institutions, small- and medium-sized enterprises, public organisations, and pharmaceutical companies.
TB Trial St Andrews has joined the approximately 40 trial sites in four continents of the UNITE4TB Consortium to deliver novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens.
In UNITE4TB, the University of St Andrews will contribute to the improvements of tuberculosis clinical trials by researching new methods to monitor response to treatment.
Funders
The European and Developing Countries Clinical Trial Partnership (EDCTP) has been one of our main donors in the past years. Their direct or indirect contribution through the PanACEA Consortium has helped us to deliver clinical trials, capacity development, and community engagement activities, pieces of training and PhD and MSc studentships.
EDCTP is currently funding the St Andrews-led clinical trial, SimpliciTB with 12 million euros.
Sponsors
TB Alliance is a non-profit organisation dedicated to the discovery, development and delivery of better, faster acting and affordable tuberculosis drugs that are available to those who need them. (Text taken from TB Alliance webpage).
Our partnership with TB Alliance has led to the delivery of clinical trials such as the STAND and REMoxTB in the past and it is the funder of our currently running clinical study, SimpliciTB.